Search PubMedSearch

PubMed · 2928984

[Therapy using dermatologic agents].

Abstract

With dermal preparations the therapeutic effect of the active ingredient is considerably influenced by factors such as the properties of the base and the type and conditions of the skin. In this respect, the correlation between the effect of the bases and the acuteness of the disease is the following: the more acute the disease, the more important the base and the less important the active ingredient. For dermal preparations there is consequently a therapeutic need for a differentiated spectrum of suitable bases. The choice of the appropriate vehicle plays a considerable role in the success of the treatment. The criteria for the selection of suitable vehicles are discussed on the basis of various examples.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Pflugshaupt. 1989. [Therapy using dermatologic agents].. https://pubmed.ncbi.nlm.nih.gov/2928984/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Monitoring for adverse effects from systemic drugs used in dermatology.

Systemic drugs with an associated element of risk are essential in managing many important dermatoses. This review identifies eight major drugs or drug groups used in dermatology that require systematic monitoring for adverse effects. The complete monitoring process is emphasized, including significant patient involvement in reporting key signs or symptoms that allow early diagnosis of many of these adverse effects. The concepts of "risk-risk" assessment and "critical toxicities" are defined, emphasizing their important role in maximizing drug benefits and safety. Drug-related risk factors, disease-specific risk factors, and patient characteristics or habits that increase the risks from systemic drugs are identified. Basic principles of monitoring for adverse effects, specific clinical features of the most important adverse effects, along with detailed monitoring guidelines for methotrexate, retinoids, dapsone, corticosteroids, and cyclosporine are presented.

Dermatologic Agents

Treatment of reticulate acropigmentation of Kitamura with azelaic acid. An immunohistochemical and electron microscopic study.

No successful therapy has been reported for reticulate acropigmentation of Kitamura, which is an autosomal dominant dermatosis. We treated a patient with 20% azelaic acid ointment. Within several weeks the pigmentation was remarkably decreased and no side effects were observed. Histologic examination revealed an increased number of dopa-positive melanocytes. These cells reacted strongly to staining with antityrosinase antibody or antityrosinase-related protein antibody. Electron microscopic findings showed many melanosomes within melanocytes, keratinocytes, and melanophages. These findings suggest that the hyperpigmentation of reticulate acropigmentation of Kitamura is the result of an excess amount of melanin production caused by activation of melanocytes in the basal layer.

Dermatologic Agents